Bristol-Myers Squibb (BMY) has been experiencing a notable increase in share price, drawing increasing attention from a host of investors globally. Top
investment firms including DNB Asset Management AS, Harvest Portfolios Group Inc, and Quantbot Technologies LP have significantly boosted their holdings in Bristol-Myers. This shift comes amid various indicators of the firm's robust momentum in the market and an optimistic outlook for its
2024 Results and Product Pipeline. Most prominent among the advancements propelling this traction is the
US FDA acceptance of priority review for BMY's Iberdomide. Furthermore, stellar growth in the firm's late-stage pipeline, spearheaded by BMY's breakthroughs in
Breast Cancer therapeutics, has considerably elevated its appeal to the investor community. However, despite the beckoning bullish narrative crafted by its Q4 2025 earnings preview and profit rebound, experts caution potential investors regarding the firm's share pricing in the context of its recent share price rebound.
Bristol-Myers Squibb BMY News Analytics from Thu, 11 Sep 2025 07:00:00 GMT to Sat, 28 Feb 2026 23:34:29 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 3
